Close Menu

licensing agreement

The license is part of an ongoing cancer research collaboration between NovellusDx and Christiana Care's Gene Editing Institute.

The deal between GE, the Global Good Fund, and Access Bio is to manufacture and distribute malaria diagnostic technologies in low-resource nations.

The assay combines high-throughput drug screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match patients with drug therapies.

The assay employs nanoplasmonics and protein-signal multiplexing in taking aim at early clinical detection of pancreatic ductal adenocarcinoma.  

Nova Satra said it will use the EpiSwitch technology to develop and commercialize non-invasive breast cancer testing across 13 territories in Asia.

The technology uses Thermo Fisher Scientific microarrays to measure transcript levels in order to diagnose rejection of solid organ transplants.

The firm is seeking funding to commercialize a malondialdehyde-acetaldehyde-adduct biomarker ELISA that it believes can help broaden access to cardiac tests.

The contract includes a milestone of approval by the Chinese Food and Drug Agency within the next three years.

MDxHealth will use Ghent's methylation in situ hybridization technology to develop tests for urological cancers.

The firm said that the technologies it has licensed improve PCR and RT-PCR amplification of DNA and RNA.

Pages